Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 12, 2012, Pages 2622-2628

  Iwatsubo, Kosaku ^a,b   Bravo, Claudio ^a   Uechi, Masami ^c   Baljinnyam, Erdene ^a   Nakamura, Takashi ^c   Umemura, Masanari ^a   Lai, Lo ^a   Gao, Shumin ^a   Yan, Lin ^a   Zhao, Xin ^a   Park, Misun ^a   Qiu, Hongyu ^a   Okumura, Satoshi ^a,b   Iwatsubo, Mizuka ^a   Vatner, Dorothy E ^a   Vatner, Stephen F ^a   Ishikawa, Yoshihiro ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NIHON UNIVERSITY   (Japan)

Author keywords

Adenine 9 D arabinofuranoside; Heart failure; Type 5 adenylyl cyclase inhibition

Indexed keywords

ACTIN; ADENYLATE CYCLASE; ADENYLYL CYCLASE 5; ADENYLYL CYCLASE 6; CADHERIN; CYCLIC AMP; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UNCLASSIFIED DRUG; VIDARABINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; LONGEVITY; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRESS; TRANSGENIC MOUSE; WILD TYPE;

ADENYLATE CYCLASE; ANIMALS; ANTIVIRAL AGENTS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEART; HEART FAILURE; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MYOCARDIUM; VIDARABINE;

EID: 84862661174     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00190.2012     Document Type: Article

References (16)

1. Balakumar P, Singh AP, Singh M. Rodent models of heart failure. J Pharmacol Toxicol Methods 56: 1-10, 2007.
2. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 101: 558-569, 2000.
3. Depre C, Wang L, Sui X, Qiu H, Hong C, Hedhli N, Ginion A, Shah A, Pelat M, Bertrand L, Wagner T, Gaussin V, Vatner SF. H11 kinase prevents myocardial infarction by preemptive preconditioning of the heart. Circ Res 98: 280-288, 2006.
4. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632, 1998.
5. Hu CL, Chandra R, Ge H, Pain J, Yan L, Babu G, Depre C, Iwatsubo K, Ishikawa Y, Sadoshima J, Vatner SF, Vatner DE. Adenylyl cyclase type 5 protein expression during cardiac development and stress. Am J Physiol Heart Circ Physiol 297: H1776-H1782, 2009.
6. Iwatsubo K, Minamisawa S, Tsunematsu T, Nakagome M, Toya Y, Tomlinson JE, Umemura S, Scarborough RM, Levy DE, Ishikawa Y. Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration. J Biol Chem 279: 40938-40945, 2004.
7. Okumura S, Kawabe J, Yatani A, Takagi G, Lee MC, Hong C, Liu J, Takagi I, Sadoshima J, Vatner DE, Vatner SF, Ishikawa Y. Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasym-pathetic and calcium-mediated cardiac regulation. Circ Res 93: 364-371, 2003.
8. Okumura S, Takagi G, Kawabe J, Yang G, Lee MC, Hong C, Liu J, Vatner DE, Sadoshima J, Vatner SF, Ishikawa Y. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci USA 100: 9986-9990, 2003.
9. Okumura S, Vatner DE, Kurotani R, Bai Y, Gao S, Yuan Z, Iwatsubo K, Ulucan C, Kawabe J, Ghosh K, Vatner SF, Ishikawa Y. Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catechol-amine stress. Circulation 116: 1776-1783, 2007.
10. Salomon Y, Londos C, Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem 58: 541-548, 1974.
11. Szabó J, Csáky L, Szegi J. Experimental cardiac hypertrophy induced by isoproterenol in the rat. Acta Physiol Acad Sci Hung 46: 281-285, 1975.
12. Tamaoki J, Tagaya E, Kawatani K, Nakata J, Endo Y, Nagai A. Airway mucosal thickening and bronchial hyperresponsiveness induced by inhaled beta 2-agonist in mice. Chest 126: 205-212, 2004.
13. Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley D, Nahmias AJ, Soong SJ. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 314: 144-149, 1986.
14. Xie LH, Chen F, Karagueuzian HS, Weiss JN. Oxidative-stress-induced afterdepolarizations and calmodulin kinase II signaling. Circ Res 104: 79-86, 2009.
15. Yan L, Vatner DE, O'Connor JP, Ivessa A, Ge H, Chen W, Hirotani S, Ishikawa Y, Sadoshima J, Vatner SF. Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 130: 247-258, 2007.
16. Yoo B, Iyengar R, Chen Y. Functional analysis of the interface regions involved in interactions between the central cytoplasmic loop and the C-terminal tail of adenylyl cyclase. J Biol Chem 279: 13925-13933, 2004.